#USA #New York #Class Action #Bronstein Gewirtz #Baxter International

Baxter International Faces Class Action Lawsuit

On October 20, 2025, the law firm Bronstein, Gewirtz & Grossman, LLC announced that they are representing investors in a class action lawsuit against Baxter International, Inc., a leading healthcare company listed on the NYSE under the symbol BAX. The lawsuit has been triggered by significant losses incurred by investors who purchased Baxter securities during a specified period.

Case Background

The proposed class period spans from February 23, 2023, to July 30, 2025. During this time, it is alleged that Baxter International and certain of its officers engaged in misleading behaviors that misrepresented the safety and efficacy of their products, specifically the Novum LVP, an infusion pump widely used in medical settings.

The complaint contends that Baxter was aware of multiple systemic defects affecting the Novum LVP, such as instances of underinfusion, overinfusion, and instances where no fluids were delivered at all—issues that pose life-threatening risks to patients. Additionally, it claims that the company had received reports of serious injuries and even fatalities connected to these issues. Despite being informed about these defects, Baxter allegedly failed to take adequate measures to rectify the risks, relying instead on insufficient customer alerts regarding the safety of their devices.

Allegations and Claims

Investors are claiming they were misled about various aspects regarding the Novum LVP, including perceived product safety, efficacy, and favorable customer feedback. The fallout from these alleged misrepresentations has resulted in a significant risk that Baxter would need to cease sales of the problematic pumps, severely impacting the company's financial standing and investor confidence. Investors assert that statements made by Baxter during this period were materially false and misleading, pertaining to the sales prospects and safety of the Novum LVP.

Next Steps for Affected Investors

The law firm has initiated this class action to help affected investors recover their losses. Those who acquired Baxter securities during the class period may join the lawsuit by visiting Bronstein, Gewirtz & Grossman's website or contacting the firm directly. The deadline for submitting lead plaintiff requests is December 15, 2025, after which investors can still participate in the lawsuit regardless of their lead plaintiff status.

No Upfront Costs

Importantly, Bronstein, Gewirtz & Grossman operates on a contingency fee basis, meaning that they will only seek fees from any recovery the court allows if the case is successful. Investors who lost money on their Baxter investments are encouraged to check eligibility for joining the class action without financial risk.

About Bronstein, Gewirtz & Grossman

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized law firm that has successfully represented investors in securities fraud cases and shareholder derivative actions, recovering substantial amounts for clients across the United States. Investors are encouraged to follow the firm on social media platforms for more updates regarding this case.

In conclusion, Baxter International faces serious allegations that could have significant implications for its financial future and the wellbeing of its investors. If you believe you were impacted by these issues, consider reaching out to Bronstein, Gewirtz & Grossman to explore your legal options.